Insights from compassionate use of tocilizumab for COVID-19 to inform appropriate design of randomised controlled trials.
作者信息
Baker Emma H, Patel Kamal, Ball Jonathan, Edwards Sarah, Harrison Thomas S, Kaul Arvind, Koh Mickey, Krishna Sanjeev, Leaver Susannah, Kumar Vinodh, Forton Daniel M
机构信息
Institute of Infection and Immunity, St George's, University of London, London, UK.
Pharmacy and Medicines Directorate, St George's University Hospitals NHS Foundation Trust, London, UK.
出版信息
Br J Clin Pharmacol. 2021 Mar;87(3):1584-1586. doi: 10.1111/bcp.14466. Epub 2020 Jul 14.
Abstract
摘要
相似文献
1
Insights from compassionate use of tocilizumab for COVID-19 to inform appropriate design of randomised controlled trials.
Br J Clin Pharmacol. 2021 Mar;87(3):1584-1586. doi: 10.1111/bcp.14466. Epub 2020 Jul 14.
2
The shortcomings of tocilizumab in COVID-19.
Infez Med. 2020 Dec 1;28(4):465-468.
3
Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review.
Rev Recent Clin Trials. 2021;16(2):138-145. doi: 10.2174/1574887115666200917110954.
4
Is IL-6 a key cytokine target for therapy in COVID-19?
Nat Rev Immunol. 2021 Jun;21(6):337-339. doi: 10.1038/s41577-021-00553-8.
5
Tocilizumab prescribing criteria for COVID-19 patients.
Hum Vaccin Immunother. 2021 Apr 3;17(4):1128. doi: 10.1080/21645515.2020.1822137. Epub 2020 Oct 20.
6
Tocilizumab for the Treatment of COVID-19-Induced Cytokine Storm and Acute Respiratory Distress Syndrome: A Case Series From a Rural Level 1 Trauma Center in Western Pennsylvania.
J Investig Med High Impact Case Rep. 2021 Jan-Dec;9:23247096211019557. doi: 10.1177/23247096211019557.
7
Serious adverse events with tocilizumab: Pharmacovigilance as an aid to prioritize monitoring in COVID-19.
Br J Clin Pharmacol. 2021 Mar;87(3):1533-1540. doi: 10.1111/bcp.14459. Epub 2020 Jul 26.
8
Hyperinflammation in COVID-19 Obese Patients Treated With Tocilizumab: A Successful Case Series.
J Investig Med High Impact Case Rep. 2021 Jan-Dec;9:23247096211037442. doi: 10.1177/23247096211037442.
9
Use of the interleukin 6 inhibitor tocilizumab in Japanese patients with cytokine release syndrome caused by COVID-19-related acute respiratory distress syndrome: A case series.
Respir Investig. 2020 Nov;58(6):510-512. doi: 10.1016/j.resinv.2020.09.006. Epub 2020 Oct 7.
10
The COVIRL002 Trial-Tocilizumab for management of severe, non-critical COVID-19 infection: A structured summary of a study protocol for a randomised controlled trial.
Trials. 2020 Sep 3;21(1):758. doi: 10.1186/s13063-020-04680-w.
引用本文的文献
1
Does tocilizumab have an effect on the clinical outcomes in COVID-19 patients? A meta-analysis of randomized control trials.
J Pharm Policy Pract. 2023 Nov 20;16(1):151. doi: 10.1186/s40545-023-00662-w.
2
The impact of immunosuppressive therapy on secondary infections and antimicrobial use in COVID-19 inpatients: a retrospective cohort study.
BMC Infect Dis. 2023 Nov 17;23(1):808. doi: 10.1186/s12879-023-08697-9.
3
International Country-Level Trends, Factors, and Disparities in Compassionate Use Access to Unlicensed Products for Patients With Serious Medical Conditions.
JAMA Health Forum. 2022 Apr 15;3(4):e220475. doi: 10.1001/jamahealthforum.2022.0475. eCollection 2022 Apr.
4
Efficacy and safety of current treatment interventions for patients with severe COVID-19 infection: A network meta-analysis of randomized controlled trials.
J Med Virol. 2022 Apr;94(4):1617-1626. doi: 10.1002/jmv.27512. Epub 2021 Dec 18.
本文引用的文献
1
Effective treatment of severe COVID-19 patients with tocilizumab.
Proc Natl Acad Sci U S A. 2020 May 19;117(20):10970-10975. doi: 10.1073/pnas.2005615117. Epub 2020 Apr 29.
2
Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure.
Cell Host Microbe. 2020 Jun 10;27(6):992-1000.e3. doi: 10.1016/j.chom.2020.04.009. Epub 2020 Apr 21.
3
COVID-19: consider cytokine storm syndromes and immunosuppression.
Lancet. 2020 Mar 28;395(10229):1033-1034. doi: 10.1016/S0140-6736(20)30628-0. Epub 2020 Mar 16.
4
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.
Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11.
5
Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China.
Clin Infect Dis. 2020 Jul 28;71(15):762-768. doi: 10.1093/cid/ciaa248.
6
Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China.
Intensive Care Med. 2020 May;46(5):846-848. doi: 10.1007/s00134-020-05991-x. Epub 2020 Mar 3.
7
Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome.
Expert Rev Clin Immunol. 2019 Aug;15(8):813-822. doi: 10.1080/1744666X.2019.1629904. Epub 2019 Jun 20.
8
C-reactive protein: a critical update.
J Clin Invest. 2003 Jun;111(12):1805-12. doi: 10.1172/JCI18921.
Zotero 插件